New hope for PTSD? antidepressant vilazodone put to the test
NCT ID NCT05948579
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tests whether the antidepressant vilazodone can safely reduce PTSD symptoms in 200 active-duty service members, veterans, and civilians. Participants receive either vilazodone or a placebo for 12 weeks, with symptom severity measured using a standard PTSD scale. The goal is to see if vilazodone improves symptoms without increasing suicidal thoughts.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vilazodone (an antidepressant)
What this could lead to
If it works, this could provide a new medication option to reduce PTSD symptoms in military and civilian populations.
What could go wrong
This is an early Phase 2 trial with only 200 participants, so results may not apply broadly. Vilazodone may cause side effects like nausea or insomnia, and it is not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST TRAUMATIC STRESS DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••